IP Library Granted Patent US 8,426,473
Granted Patent B2
US 8,426,473 · App. 13/466,191 · Granted Apr 23, 2013

Phenoxy acetic acids as PPAR delta activators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,426,473
App. No.
13/466,191
Granted
Apr 23, 2013
Kind
B2
Abstract

The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy-acetic acids are activators of PPAR-δ and should be useful for treating conditions mediated by the same.

Claims (4)

1. A method of treating a renal disease selected from the group consisting of glomerulonephritis, glomerulosclerosis, nephrotic syndrome, and hypertensive nephrosclerosis comprising: administering to a human subject {4-[3-isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof.

2. A method of treating a renal disease selected from the group consisting of glomerulonephritis, glomerulosclerosis, nephrotic syndrome, and hypertensive nephrosclerosis comprising: administering to a human subject {4-[3-isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof.

3. A method of treating a cardiovascular disease selected from the group consisting of atherosclerosis, mortality reduction, coronary artery disease, coronary heart diseases, heart attack, myocardial ischemia, myocardial infarct, coronary infarct, transient ischemic attack (TIA), and stroke comprising: administering to a human subject {4-[3-isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-phenylsulfanyl]-2-methyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof.

4. A method of treating a cardiovascular disease selected from the group consisting of atherosclerosis, mortality reduction, coronary artery disease, coronary heart diseases, heart attack, myocardial ischemia, myocardial infarct, coronary infarct, transient ischemic attack (TIA), and stroke comprising: administering to a human subject {4-[3-isobutoxy-5-(3-morpholin-4-yl-prop-1-ynyl)-benzylsulfanyl]-2-methyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof.

Assignments (8)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 036254 FRAME: 0792. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 24, 2015
From: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
To: VTVX HOLDINGS II LLC
Reel/Frame 036675/0399 →
RELEASE OF SECURITY INTEREST Recorded Aug 3, 2015
From: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
To: VTVX HOLDINGS I LLC
Reel/Frame 036254/0792 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2015
From: VTVX HOLDINGS II LLC
To: VTV THERAPEUTICS LLC
Reel/Frame 036242/0362 →
CHANGE OF NAME Recorded Jul 30, 2015
From: HIGH POINT PHARMACEUTICALS, LLC
To: VTVX HOLDINGS II LLC
Reel/Frame 036236/0159 →
SECURITY INTEREST Recorded Feb 26, 2015
From: HIGH POINT PHARMACEUTICALS, LLC
To: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
Reel/Frame 035103/0029 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2012
From: EBDRUP, SOREN
To: NOVO NORDISK A/S
Reel/Frame 028437/0514 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2012
From: NOVO NORDISK A/S
To: TRANSTECH PHARMA, INC.
Reel/Frame 028437/0538 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2012
From: TRANSTECH PHARMA, INC.
To: HIGH POINT PHARMACEUTICALS, LLC
Reel/Frame 028437/0552 →